Dr. John Cush RheumNow
4 years 5 months ago
RheumNow's PsA Campaign with enhanced coverage of Psoriatic Disease is sponsored by Janssen. All content is chosen by RheumNow + its faculty. #PsAlways https://t.co/gHmZs3SW9S
Dr. John Cush RheumNow
4 years 5 months ago
Join us on April 12th for Tuesday Night Rheumatology at 7pm ET.
This week will host a conversation between Dr. Cush and Dr. Artie Kavanaugh on PsA medical journal articles.
Register today: https://t.co/YQD598xt7X https://t.co/k5uDeojEh7
Dr. John Cush RheumNow
4 years 5 months ago
Depression was studied in 208 #PSA patients - Depression was found in 30%. Depression risk was higher in those with higher disease activity (DAPSA; P=.007) and functional impairment (HAQ-DI; p=-.02) https://t.co/0bZ2xPprTp https://t.co/Gdiic5iKCi
Dr. John Cush RheumNow
4 years 5 months ago
Survey Question for RHEUMATOLOGISTS ONLY - Glucocorticoids are only used in #PsA under what circumstance? ANSWER here>> https://t.co/lqdZilbogR https://t.co/XxnOu9cQk3
Dr. Jack Cush reviews the news and journal articles from the past week and discusses the use of fibroscan in RA, steroid hip injections in OA and famous quotes from a famous cardiologist.
Dr. John Cush RheumNow
4 years 5 months ago
I signed up for a great LUPUS Symposia on Saturday May 7th. Its all about the future of #SLE! You should register. Check out the all-start faculty! Drs. Chakravarty, Clowse, Costenbader, Furie, James, Kalunian, Kim, Merrill, Mohan, Pascual, Petri https://t.co/eZIJoEEzo9 https://t.co/09Da4kEUUF
Dr. John Cush RheumNow
4 years 5 months ago
CorEvitas Registry study of Axial #PsA pts showed 6 mos of bDMARD/tsDMARD resulted in modest, nonsignificant improvement axial outcomes,(irrespective HLA-B27 status), including ASDAS40, BASDAI50, & spinal pain. 31% of pts were B27+ https://t.co/9m9H7PwIIF #PsAlways https://t.co/dYk5GfIdez
Dr. John Cush RheumNow
4 years 5 months ago
FDA has granted a Priority Review for tocilizumab (Actemra) intravenous for the treatment of hospitalised COVID-19 adults receiving systemic corticosteroids and require supplemental O2, mechanical ventilation, or ECMO. https://t.co/b4GSuvsElp https://t.co/oEGskAJVyd
Dr. John Cush RheumNow
4 years 5 months ago
COMPLETE-PsA Trial studied MTX vs MTX + leflunomide in 78 active untreated PsA pts. MTX+LEF was superior to MTX alone at wk 16 (PASDAS 3·1 vs 3·7; p=0·025). Combo group had more N/V (44% v 28%), ^ALT (31% vs 18%). https://t.co/Hc4rNrlQzP https://t.co/UPosZIc4C0
Dr. John Cush RheumNow
4 years 5 months ago
Deucravacitinib, TYK2 inhib, studied in phase II trial 203 active PsA pts randomised to PBO, or DEUC 6 mg or 12 mg qd. At wk 16 ACR-20 responses were significantly higher with DEUC 6mg (53%, p=0.0134) and 12 mg (63%, p=0.0004) vs PBO. https://t.co/0nvutsXHsI https://t.co/jh43zCbdZx
Dr. John Cush RheumNow
4 years 5 months ago
Differences between Palpated & Ultrasound Joint exams in 155 #PSA patients. 5616 joints - found 18.5% tender, 9.8% swollen, 20.4% w/ US GS ≥ 2 and 5.2% had US PD ≥ 1. Joints that were both tender and swollen more likely to have GS ≥ (44%) https://t.co/nWI7jLdkWp https://t.co/iRNsqWYScM
Dr. John Cush RheumNow
4 years 5 months ago
Rheum Comanagement of Psoriasis
https://t.co/vXF4t2IIoW
QD Clinic is sponsored by RheumNow's PsA All the Way Campaign in April 2022 https://t.co/fDVx49XtYP
Dr. John Cush RheumNow
4 years 5 months ago
“Do as much as possible for the patient, & as little as possible to the patient.” (B Lown). JAMA review of Antithrombotics in COVID-19 says all hospitalized COVID pts with COVID-19 should recv anticoagulation with heparin; no proven value to anti-Plts Rx https://t.co/ZfaH4FiRy1 https://t.co/DW8BGKjfnX
When it comes to psoriatic arthritis clinical trials such as TICOPA (tight control in PsA) have consistently shown that treating to target correlates with improved disease domain and patient reported outcomes. Minimal disease activity (MDA) has become an oft used target and outcome in PsA trials. While many of us measure and record a variety of measures in our patient charts, we may be on our way to demonstrating MDA in practice.
